ONE-DAY VIRTUAL CONFERENCE




CANM VIRTUAL CONFERENCE- NOVEMBER 7, 9 AM- 4:15 PM ET


Program

Overall objectives of the one-day virtual conference:

  • 1.   Maintain competence on a wide variety of up-to-date topics in Nuclear Medicine
  • 2.   Discuss hot new topics
  • 3.   Establish a network of Nuclear Medicine specialists
  • 4.   Promote Nuclear Medicine as a specialty

25% of allowed time to each speaker will be reserved for questions from participants.


 TIME  TITLE  SPEAKER  CHAIR / MODERATOR
 0900-0915  Welcome & instructions    Jean-Luc Urbain & Andrew Ross
0915-0945  Personal Dosimetry & Theranostics Helena McMeekin Andrew Ross
0945-1000  Q & A    
1000-1030  Digital Technology Advantages Gil  Kovalski Jean-Luc Urbain
1030-1045  Q & A    
1045-1100  BREAK    
1100-1130  Lutathera: the primers  Jennifer Schroeder  Jean-Luc Urbain
1130-1145  Q & A    
1145-1300  BREAK    
1300-1330  The Evolution of Positron Emission   Tomography  Éric Turcotte  Andrew Ross
1330-1345  Q & A    
1345-1415  Treatment of Neuroendocrine Tumors  Shereen Ezzat   Jean-Luc Urbain
1415-1430  Q & A    
1430-1445  BREAK    
1445-1515  Cardiac Theranostics  Jean-Luc Urbain  Andrew Ross
1515-1530  Q & A    
1530-1600  Cardiac Amyloidosis  Sharmila Dorbala  Jean-Luc Urbain
1600-1615  Q & A    
Faculty List


Dorbala, Sharmila


Sharmila Dorbala, MD, MPH is the Director of Nuclear Cardiology at Brigham and Women’s Hospital, and Associate Professor of Radiology at Harvard Medical School. As a cardiovascular imaging specialist, she practices cardiac SPECT, PET, and echocardiography and her research is focused on cardiac amyloidosis. Dr. Dorbala is the current President of the American Society of Nuclear Cardiology.

She is an Associate Editor of the Journal of Nuclear Cardiology and a past Associate Editor of Circulation Cardiovascular Imaging. Dr. Dorbala has authored or coauthored more than 150 articles, abstracts, and presentations. She is passionate about teaching Nuclear Cardiology and has given more than 200 presentations at facilities and medical society meetings regionally, nationally, and internationally. She has served as a principal investigator for several clinical research studies in cardiac amyloidosis imaging withresearch funding from the National Institutes of Health, the American Heart Association, Foundation, Philanthropic, and Industry grants.


 

Ezzat, Shereen


Shereen Ezzat, M.D., FRCP(C), FACP, Professor of Medicine & Oncology, Endocrine Oncology Site Group, Princess Margaret Cancer Centre, University Health Network.  Dr. Ezzat obtained his medical degree from the University of Manitoba, completed his residency training at the University of British Columbia, and his post-doctoral research training in molecular oncology at Cedars-Sinai-UCLA School of Medicine in Los Angeles.

Dr. Ezzat has authored or co-authored more than 250 original research articles and 40 invited review articles, and he has delivered more than 150 invited lectures. He supervises undergraduate and graduate students, as well as postdoctoral fellows. He teaches a number of courses, including physiology, biochemistry, and developmental biology.

Dr. Ezzat served as an Editorial Board member for a number of journals including Endocrinology, Journal of Clinical Endocrinology & Metabolism, American Journal of Physiology, Journal of Endocrinology, Endocrine Practice, and BMJ-Endocrine. He is a regular reviewer for the New England Journal of Medicine and the Annals of Internal Medicine.

Dr. Ezzat belongs to a number of professional societies, including the Endocrine Society, Federation of American Societies for Experimental Biology (FASEB), the Pituitary Society, the American College of Physicians, and the Royal College of Physicians & Surgeons of Canada.   He is equally committed to patient advocacy and serves as an advisor to a number of organizations including the Canadian Neuroendocrine Tumor Society (CNETS), Thyroid Cancer Canada, and the Pituitary Network Association.



 

Kovalski, Gil


Gil Kovalski is the global clinical applications leader for Molecular Imaging at GE Healthcare which includes PET/CT, SPECT/CT and Digital solutions.

Gil joined GE in 1999.

Gil holds a MSc & PhD in Biomedical Engineering and BSc degrees in Pre-Med and Computer Science.

Gil’s scientific papers were mostly focused in the domain of nuclear cardiology technology.

 

McMeekin, Helena MSc.


Helena is a UK state-registered clinical scientist specialising in nuclear medicine physics. She enjoyed working in the Royal Free Hospital and the National Amyloidosis Centre in London, developing her skills in all areas of nuclear medicine and PET/CT physics and publishing research focusing on GFRs and patient specific activity optimisation for FDG PET/CT. She is the lead author on publications supporting the move from multiple sample to single sample GFR in the 2018 BNMS GFR guidelines.

Helena currently works part time for Barts Health NHS Trust as Principle Physicist for Nuclear Medicine and PET/CT, and for Hermes Medical Solutions as a Clinical Applications Scientist. For Hermes, her area of expertise is oncology and dosimetry software; her passion for clinical research continues at St Bartholomew’s Hospital.



 

Schroeder, Jennifer Anne


Medical School:  Medical University of South Carolina, 2014
Radiology Residency:  Wake Forest Baptist Medical Center, 2019
Nuclear Fellowship:  University of Pennsylvania, 2020
Current Position:  Assistant Professor of Nuclear Radiology at Wake Forest Baptist Medical Center
Interests:  Theragnostic, hybrid imaging

 

Turcotte, Eric


Many in medical community regard Dr Eric Turcotte as a leading authority and much-sought-after speaker on PET scan and PET tracer development.  His enthusiastic approach helps him to quickly connect with patients and scientists and make an impact.

Dr Turcotte graduated from University of Sherbrooke School of Medicine and completed his specialist training in Nuclear medicine.  He continued with post-doctoral fellowship in Nuclear medicine at University of Washington, Seattle (WA).

Dr Turcotte has over twenty years of experience in medical practice.  He practices medicine at Nuclear medicine department at Centre hospitalier Universitaire de Sherbrooke (CHUS) and is an Associate Professor at the University of Sherbrooke. He teaches nuclear medicine and PET imaging to students from Canada and around the world, as well as to many Canadian nuclear medicine specialists seeking special training in PET. As the head of Clinical research at Sherbrooke Molecular Imaging Centre (CIMS), Dr Turcotte has lead more than 30 clinical research studies. Dr Turcotte has been a contributing writer for books, has published dozens of articles, and speaks extensively on PET scan imagery and tracer development. 

Dr Turcotte is the leader of 8 clinical trial applications with Health Canada testing the diagnostic efficiency of newly developed PET tracers. His work also includes taking newly developed radiotracers from the pre-clinical development stage to a final human imaging or therapeutic modality phase. He also holds an establishment license from Health Canada to operate one of the most advanced PET radiotracer synthesis facilities in Canada.



 

Urbain, Jean-Luc


A native of Belgium, Dr. Urbain earned his Medical Degree at the University of Louvain, Belgium, and then pursued residency training in Internal Medicine and Nuclear Medicine at the University Hospital of the University of Louvain in Brussels, Belgium. He subsequently obtained a Ph.D. in Genetics and Molecular Biology at Temple University in Philadelphia. 

Professor of Imaging, Medicine and Biology for more than two decades, Dr. Urbain has held leadership and executive positions in Medical Imaging and Medicine in Belgium at the University of Leuven, in Canada at the University of Western Ontario and in the US at Temple University, Fox Chase Cancer Center, The Cleveland Clinic, the VA Administration and now Wake Forest University/Baptist Medical Center. During his career he had the opportunity and privilege to visit hospitals and medical centers and give lecture on all continents. 

Dr. Urbain has extensive experience and expertise in committees and boards leadership, in the management of integrated health care systems and patient advocacy groups and at regional, national and international levels of government. He has also served as consultant and advisor for Pharmaceutical, Radiopharmaceutical and Medical Systems companies. He worked closely with national and international medical associations and government health authorities to mitigate the major health and medical isotopes crises of 2007-2008, analyzed and helped establish medical resources needs, benchmarks and allocation for key medical service areas. 

Dr. Urbain was appointed as Secretary of the Belgian Society of Nuclear Medicine in the early 90s’, President of the Canadian Association of Nuclear Medicine (CANM 2006-2011) and President of the Easter Great Lakes Chapter of the SNMMI (2010-2012). Starting on January 1st, 2021 he will assume the Presidency of the World Federation of Nuclear Medicine and Biology.

His current interests are in Precision Medicine and Theranostics, Graduate and Postgraduate Physicians Education, Patients’ Education and Advocacy.

 


Powered by Wild Apricot Membership Software